{"product_id":"amgen-five-forces-analysis","title":"Amgen Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmgen operates in a capital‑intensive, innovation-driven biotech sector where high R\u0026amp;D barriers and scale advantages temper new entrants, while powerful payers and strategic partners shape pricing and market access.\u003c\/p\u003e\n\u003cp\u003eCompetition from big pharmas and biosimilars elevates rivalry, supplier power is moderate, and substitutes pose niche threats tied to novel modalities.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Amgen’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized biologics inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen depends on niche biologics inputs—cell lines, GMP growth media, viral vectors—with few qualified suppliers, raising switching costs and supply risk; concentrated supply gives vendors leverage on pricing and contract terms. Single-\/few-source components have forced Amgen to use dual-sourcing, inventory buffers and multi-year supply agreements; Amgen reported roughly $26.5B revenue in 2024, underpinning its procurement investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioreactors and single-use systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-spec bioreactors, chromatography resins and single-use bags\/filters are concentrated among Cytiva (Danaher), Sartorius, Thermo Fisher and Merck, which strengthens supplier leverage. Qualification and validation create vendor lock-in and lead times of several months, limiting Amgen’s flexibility. Amgen mitigates this via volume-based contracts and platform standardization to reduce dependency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSelective outsourcing of biologics production and fill-finish to CDMOs with constrained sterile-injectable capacity shifts bargaining power to suppliers, as tight global capacity raises lead times and premiums. Regulatory re-approval for site transitions increases switching costs, so Amgen mitigates risk by combining large in-house manufacturing scale with selective outsourcing and multi-site redundancy to preserve supply resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary tech and licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpupstream and downstream process technologies enabling ip such as expression systems often require third-party licenses letting owners command royalties restrictive covenants that embed supplier power into cogs program timelines. amgen noted in its filings continued investment internal platforms co-development to reduce royalty burdens timeline risk. class=\"lst_crct\"\u003e\u003cli\u003eLicensing drives recurring royalties impacting gross margin\u003c\/li\u003e\u003cli\u003eRestrictive covenants can delay scale-up\u003c\/li\u003e\u003cli\u003e2024 filings: increased platform investment to internalize IP\u003c\/li\u003e\n\u003c\/pupstream\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized scientific talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetition for biologics CMC, AI\/ML and cell\/gene therapy experts is intense, and scarcity empowers talent suppliers to demand premium compensation and flexible terms. Retention directly affects knowledge capital and continuity of GMP operations. Amgen counters with defined career pathways, regional hubs, and global recruitment, supporting ~26,600 employees (2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh demand → premium pay and flexible contracts\u003c\/li\u003e\n\u003cli\u003eTurnover risk → GMP continuity and knowledge loss\u003c\/li\u003e\n\u003cli\u003eAmgen actions → career paths, hubs, global hiring; ~26,600 employees (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration raises switching costs; \u003cstrong\u003e$26.5B\u003c\/strong\u003e backs supply resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen faces strong supplier power for niche biologics inputs, single-use systems and CDMO capacity, raising switching costs and pricing pressure; 2024 revenue ~$26.5B supports long-term supply contracts and inventory buffers. Supplier concentration (Cytiva, Sartorius, Thermo Fisher, Merck) and licensed IP drive royalties and lead times; Amgen balances this with internal platform investment and multi-site redundancy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$26.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e26,600\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey suppliers\u003c\/td\u003e\n\u003ctd\u003eCytiva, Sartorius, Thermo Fisher, Merck\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter’s Five Forces analysis for Amgen, uncovering competitive intensity, buyer and supplier power, threats from substitutes and new entrants, and highlighting disruptive forces and strategic moats that shape pricing, profitability, and market defense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise one-sheet Porter's Five Forces for Amgen—quickly highlights competitive pressures, supplier\/payer leverage, biosimilar\/new entrant threats and regulatory impact so teams can prioritize strategic responses and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and PBMs consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsolidation of payers and the three largest PBMs (CVS Caremark, Express Scripts, Optum Rx) handling roughly 80% of US prescription claims sharpens customer bargaining power, enabling aggressive formulary placement, rebates and utilization rules. Their scale boosts price sensitivity and leverage over net pricing, with step edits and prior authorizations commonly restricting uptake. Amgen counters via outcomes data, value-based contracting and real-world evidence to defend access and pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare’s Inflation Reduction Act requires manufacturers to rebate price increases above CPI to Medicare (effective 2023) and establishes Medicare drug price negotiation starting 2026, tightening U.S. net prices over time. Public tenders and HTA bodies abroad impose cost‑effectiveness thresholds (NICE £20,000–30,000\/QALY in 2024), and biosimilar penetration often exceeds 50% in EU markets, driving down mature‑brand prices. Buyers thus exert significant downward pressure on Amgen’s established franchises; Amgen responds with comparative‑effectiveness studies and detailed value dossiers to defend reimbursements and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvider systems and GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated delivery networks and GPOs—GPOs represent over 90% of US hospitals and roughly two-thirds of hospitals belong to health systems—aggregate purchasing power to demand discounts, biosimilar adoption (uptake in some biologic classes now exceeds 50%), and inventory efficiencies. Purchasing decisions are increasingly standardized across networks, forcing Amgen to compete on contracting, bundled service models, and supply reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient cost sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient out-of-pocket exposure strongly affects initiation and adherence in high-cost biologics; 2024 surveys show about 30% of US patients delay or abandon therapy for cost reasons, creating pressure to lower list and net prices. Advocacy and assistance programs shift access expectations. Amgen uses copay support, HUB services and affordability programs to sustain demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOOP sensitivity ~30%\u003c\/li\u003e\n\u003cli\u003eAdvocacy raises affordability demands\u003c\/li\u003e\n\u003cli\u003ePressure on list and net prices\u003c\/li\u003e\n\u003cli\u003eAmgen: copay cards, HUB, patient affordability programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-driven access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBargaining power of customers forces Amgen to supply robust RWE, head-to-head trials, and value-based arrangements as payers and health systems demand demonstrated outcomes; lacking differentiation invites step therapy or placement on non-preferred tiers. Demonstrated outcomes can secure preferred status, and Amgen’s 2024 global revenue of about $28.4 billion underpins continued investment in biomarkers, HEOR, and risk-sharing contracts to align with buyer metrics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuyers demand: RWE, head-to-head trials, VBCs\u003c\/li\u003e\n\u003cli\u003eRisk: step therapy\/non-preferred tiers if undifferentiated\u003c\/li\u003e\n\u003cli\u003eLeverage: proven outcomes = preferred status\u003c\/li\u003e\n\u003cli\u003eAmgen action: biomarkers, HEOR, risk-sharing contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated PBMs\/GPOs and IRA\/Medicare moves pressure net prices; payers push RWE and rebates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentrated PBMs (≈80% of US claims) and GPOs give buyers strong leverage over pricing and access; payers demand RWE, rebates and utilization controls. IRA rebates (since 2023) and Medicare negotiation (from 2026) tighten US net prices; EU biosimilar penetration often \u0026gt;50%. Patient OOP sensitivity ~30% pressures affordability; Amgen 2024 revenue ≈ $28.4B supports HEOR and value‑based contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM share of US claims\u003c\/td\u003e\n\u003ctd\u003e≈80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient OOP sensitivity (2024)\u003c\/td\u003e\n\u003ctd\u003e≈30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU biosimilar penetration\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmgen 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e≈ $28.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAmgen Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Amgen Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or samples. The document is fully formatted, professionally written, and ready for download and use the moment you buy. What you see here is the deliverable: complete, final, and ready to support your decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163153183097,"sku":"amgen-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/amgen-five-forces-analysis.png?v=1762715429","url":"https:\/\/portersfiveforce.com\/products\/amgen-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}